toll-like receptor

Overview

Toll-like receptors (TLRs) are a family of pattern recognition receptors (PRRs) that serve as critical sentinels of the innate immune system. First characterized in Drosophila and subsequently identified in mammals, TLRs detect conserved molecular structures known as pathogen-associated molecular patterns (PAMPs) — including bacterial lipopolysaccharide (LPS), viral double-stranded RNA, and flagellin — as well as damage-associated molecular patterns (DAMPs) released during sterile injury. Upon ligand binding, TLRs initiate intracellular signaling cascades, most prominently through the adaptor protein MyD88, leading to activation of nuclear factor kappa B (NF-κB) and downstream transcription of proinflammatory cytokines. At least thirteen mammalian TLR subtypes have been identified (TLR1–TLR13), each with distinct ligand specificities and tissue distributions; TLRs 1, 2, 4, 5, and 6 are expressed on the cell surface and recognize extracellular microbial products, while TLRs 3, 7, 8, and 9 reside in endosomal compartments and sense nucleic acids.

Beyond their canonical role in host defense, TLRs occupy a central position in immunopathology, chronic inflammation, and oncology. Dysregulated TLR signaling contributes to sepsis, autoimmune disease, neuroinflammation, and the immunosuppressive tumor microenvironment. Pharmacological modulation of specific TLR subtypes — through agonists that stimulate antitumor immunity or antagonists that dampen excessive inflammation — has therefore emerged as a major therapeutic strategy. TLR agonists are incorporated into vaccine adjuvants to boost adaptive immune responses, and several synthetic small-molecule TLR modulators are under active clinical and preclinical investigation.

Focus of Latest Publications

Recent publications highlight the breadth of contexts in which TLR signaling is being interrogated, spanning infectious disease, neurological injury, metabolic inflammation, vaccine immunology, and cancer immunotherapy.

Infection and blood-brain barrier disruption. A 2026 multi-omics study (PMID 42115138) used integrated transcriptomic and proteomic analysis to characterize host responses during meningitis-associated extraintestinal pathogenic Escherichia coli (ExPEC) infection. The investigators identified coordinated innate immune activation, with pronounced upregulation of Toll-like receptor signaling alongside NOD-like receptor, TNF, and IL-1 pathways, as well as antigen presentation machinery. These findings position TLR signaling as a central orchestrator of the neuroinflammatory cascade that disrupts the blood-brain barrier during bacterial meningitis.

Neuroinflammation in ischemia-reperfusion injury. A pharmacological study (PMID 42013993) investigated amygdalin as a candidate neuroprotectant in cerebral ischemia-reperfusion injury using a rat middle cerebral artery occlusion/reperfusion (MCAO/R) model. Integrated multi-omics analysis converged on NF-κB, Toll-like receptor, and NOD-like receptor signaling as core mechanistic pathways, with TLR4, Myd88, Nlrp3, and Caspase-1 (CASP1) identified as key molecular nodes. Amygdalin treatment attenuated activation of the TLR4/NF-κB axis and suppressed NLRP3 inflammasome assembly, linking TLR4 upstream signaling directly to downstream inflammasome-mediated neuronal injury and oxidative stress.

Vaccine immunogenicity and the TLR3 type I interferon pathway. A study in healthy adolescents and adults (PMID 42139359) examined how pre-existing variability in the TLR3-mediated type I interferon pathway predicts responses to RNA-based vaccines, including BNT162b2 mRNA vaccine and CoronaVac inactivated virus vaccine. Prevaccine immune states were assessed at the protein and transcriptomic levels following whole blood stimulation with TLR viral agonists, demonstrating that baseline TLR pathway tone is a meaningful predictor of adaptive vaccine responsiveness.

Metabolic inflammation and hepatic TLR signaling. Research on DL-norvaline (PMID 42105997) in high-fat diet-induced metabolic dysfunction found that this compound lowered circulating LPS and inflammatory mediators, attenuated hepatic activation of multiple toll-like receptors and their downstream MyD88/NF-κB signaling cascade, and restored Nrf2-associated antioxidant gene expression. These data suggest that metabolic endotoxemia — characterized by elevated bacterial LPS — chronically engages hepatic TLR signaling, and that pharmacological attenuation of this pathway can ameliorate metabolic inflammation.

Small-molecule TLR modulators. A medicinal chemistry effort (PMID 42014047) reported the design and synthesis of novel pyrazolo[1,5-c]quinazolin-5-amine scaffolds as potential modulators of Toll-like receptor 7/8 (hTLR7/8). The work demonstrated that multiple heterocyclic scaffolds can exhibit agonist or antagonist activity at TLRs with varying subtype selectivity, advancing the chemical toolkit available for therapeutic TLR modulation.

cancer immunotherapy. Two studies investigated TLR agonism in the context of antitumor immunity. An inhalable cryo-shocked tumor cell platform for chemoimmunotherapy (PMID 41947504) relied on TLR and NF-κB signaling activation by liquid nitrogen-treated tumor cells to drive proinflammatory cytokine secretion and engage the immune system against orthotopic lung cancer and aggressive pulmonary metastasis. Separately, a review on intraperitoneal delivery of TLR agonists (PMID 41926324) underscored their capacity to activate both innate and adaptive immunity — including natural killer (NK) cells and CD8+ T cells — effectively converting immunologically "cold" tumors within the tumor microenvironment into immunologically "hot" ones amenable to therapeutic attack.

Key Publications

• Jun DL-norvaline attenuated HFD-induced metabolic inflammation and dysfunction with integrated pharmacokinetic, biodistribution, and safety evaluation. (European journal of pharmacology, 2026, PMID 42105997): "DL-norvaline lowered LPS and inflammatory mediators, attenuated hepatic activation of multiple toll-like receptors and downstream MyD88/NF-κB signaling, and restored Nrf2-associated antioxidant genes."
• May Variability in the TLR3 type I interferon pathway is predictive of RNA vaccine responses. (Science advances, 2026, PMID 42139359): "To test this, we assessed prevaccine immune responses at protein and transcriptomic levels following whole blood stimulation with Toll-like receptor (TLR) viral agonists in healthy adolescents and adults."
• May Amygdalin attenuates post-ischemic neuroinflammation by targeting TLR4/NF-κB signaling and NLRP3 inflammasome in cerebral ischemia-reperfusion injury. (European journal of pharmacology, 2026, PMID 42013993): "Integrated multi-omics analysis further narrowed the candidate mechanisms to core pathways including NF-κB, Toll-like receptor, and NOD-like receptor signaling, and identified Tlr4, Myd88, Nlrp3, and Caspase-1 as key candidate molecules;"
• May Integrated transcriptomic and proteomic analysis reveals inflammatory activation and blood-brain barrier disruption during meningitis-associated extraintestinal pathogenic Escherichia coli infection. (Virulence, 2026, PMID 42115138): "Multi-omics integration revealed coordinated immune activation, with upregulation of innate immune signaling pathways such as Toll-like receptor, NOD-like receptor, TNF, and IL-1 signaling, as well as antigen presentation pathways."
• Apr Design and Synthesis of New Pyrazolo[1,5-c]quinazolin-5-amines as Potential TLR7/8 Modulators. (ChemMedChem, 2026, PMID 42014047): "Multiple heterocyclic scaffolds have been found to exhibit agonist or antagonist activity at toll-like receptors (TLRs) with varying degrees of selectivity for the subtypes."
• Apr Inhalable Cryo-Shocked Tumor Cells for Synergistic Chemoimmunotherapy. (ACS applied materials & interfaces, 2026, PMID 41947504): "...pro-inflammatory cytokine secretion via activation of Toll-like receptor (TLR) and nuclear factor kappa B (NF-κB) signaling pathways."
• Apr Leveraging intraperitoneal delivery of Toll-like receptor agonists to treat peritoneal metastases. (Expert opinion on drug delivery, 2026, PMID 41926324): "Toll-like receptor (TLR) agonists are particularly attractive due to their ability to activate both innate and adaptive immunity, effectively converting 'cold' tumors."